Lancet Haematol: Venetoclax combined with intensive chemotherapy in the treatment of AML or high-risk MDS

Adding Venetoclax, a BCL2 inhibitor, to low-intensity therapy has been shown to increase the overall survival rate of elderly (75 years or older) patients with newly diagnosed acute myeloid leukemia
.

The purpose of this study is to clarify the activity of Venetoclax combined with intensive chemotherapy in acute myeloid leukemia patients 65 years of age and younger

The cohort study was completed at the MD Anderson Cancer Center in the United States and is part of the single-center, single-arm Phase II CLIA trial
.

This article reports an independent cohort study on the safety and activity of adding Venetoclax to intensive chemotherapy

The test patients were newly diagnosed patients with previously untreated acute myeloid leukemia, mixed phenotypic acute leukemia, or high-risk myelodysplastic syndrome, aged 18-65 years old, and were given clarithromycin (5 mg/m ² ) and albine sugar cytidine (<60 years in patients with 1.
5 g / m2, ≥60 years G patient.
1 / m ² ) infusion on days 1-5, daunorubicin (10 mg / m2) for 1-3 days infusion
.

Consolidation therapy: clarithromycin (5 mg/m2) and cytarabine (1 g/m ^{2 in} patients <60 years old , 0.

^{2 2 2 2}

From February 25, 2019 to March 23, 2021, 77 patients were reviewed for eligibility, and 50 of them were included in the study
.

The median age of the tested patients was 48 years old

Forty-seven (94%) patients achieved composite complete remission, and the same proportion of patients also achieved overall remission.

Various endpoints

Various endpoints

Of the 45 patients, 37 (82%) had undetectable residual disease (MRD )
.

At a median follow-up of 13.

37 out of 45 patients (82%) had no residual disease detected (MRD 37 out of 45 patients (82%) had no residual disease detectable (at the 12th month of

Infect

In summary, for newly diagnosed patients with acute myeloid leukemia or high-risk myelodysplastic syndromes, adding Venetoclax to the intensive chemotherapy regimen is safe and effective, and can produce a high rate of durable MRD negative remission and improve event-free Survival rate and overall survival rate
.

For newly diagnosed patients with acute myeloid leukemia or high-risk myelodysplastic syndromes, adding Venetoclax to intensive chemotherapy is safe and effective, can produce a high rate of durable MRD negative remission, and improve event-free survival and overall survival Rate
.

For newly diagnosed patients with acute myeloid leukemia or high-risk myelodysplastic syndromes, adding Venetoclax to intensive chemotherapy is safe and effective, can produce a high rate of durable MRD negative remission, and improve event-free survival and overall survival Rate

Original source:

Tapan M Kadia, et al.

Venetoclax plus intensive chemotherapy with cladribine, idarubicin , and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial in this message